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ABSTRACT 
Objective: To develop method to measure both methadone enantiomers and its major metabolite 2-ethylidene-1, 5-dimethyl-3, 3-
diphenylpyrrolidine (EDDP) in clinical samples 
Methods: Five hundredmicroliters plasma/serum was extracted using solid phase extraction (mixed mode SPE-C8/SCX). The eluent was 
evaporated, reconstituted in mobile phase (95:5, 0.003% formic acid in methanol: 20 mM* ammonium formate) and injected.  
Result: The recoveries of methadone enantiomers and EDDP were 97% and 89% respectively. Under this condition, methadone enantiomers were 
successfully separated at baseline but not EDPP. Precision of spiked plasma for intra-day and inter-day was less than five for both methadone 
enantiomers and less than 12 for EDDP at medium and high quality control samples. Linear relationship between peak area ratio and internal 
standard were obtained for methadone in the range 5-1000ng/ml, and for EDDP from 5-500ng/ml with correlation coefficients greater than 0.99. 
The limit of quantification was 5ng/ml.  
Conclusion: The assay was used to analyse serum samples obtained from patients enrolled in a methadone maintenance treatment program. 
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INTRODUCTION 
Methadone was discovered in the 1930’s for use as an analgesic and 
has been used since 1960’s for the stabilization and maintenance of 
patients with addictive disorders [1]. With the advent of HIV/AIDS 
in the 1980’s, methadone became a widely used to substitute for 
illicit injectable opiates that propelled HIV spread. Over the past 10 
years, interest in its use for pain treatment has also increased. 
Methadone however has complex pharmacokinetics and 
pharmacodynamics. This contribute to the poor relationship 
between dose, plasma levels and effects and the use of therapeutic 
concentrations. Earlier studies demonstrated that methadone doses 
from 60 to 100mg/day were effective; however it is now 
increasingly acknowledged that doses larger than 100mg/day may 
be required [2]. Thus, although 100mg/day is considered a 
maximum by many physicians, doses of more than 100mg/day are 
used in an increasing number of centres. On average, researchers 
have affirmed the benefit of a 150 to 600 ng/mL trough level to 
suppress opioid craving and a trough level at or above 400 ng/mL to 
provide opioid blockade during methadone maintenance[3, 4].  
Methadone has an asymmetrical carbon atom in its structure. It 
exists as two enantiomers, having the same chemical composition 
but different spatial arrangements. It is marketed as a racemic 
mixture (50:50 mixture) of (R) or levo or l-methadone and (S) or 
dextro or d-methadone. R-methadone has 10-fold higher affinity 
than S-methadone for µ and δ opioid receptors [5]. It possesses up to 
50 times the analgesic activity of S-methadone in human and in 
animal models[6]. R-methadone prevents opioid withdrawal but 
notS-methadone[7]. HoweverS-methadone blocks the potassium 
channel 3.5-fold more potently than R-methadone to cause 
prolonged QTC and sudden death [8]. It is proposed that the 
concentration of methadone enantiomers in serum of patients on 
MMT is higher than a certain maximum to cause prolonged QTC. It is 
also proposed that a therapeutic range exists for R-methadone for 
optimal effectiveness. Availability of a method to simultaneously 
measure methadone enantiomers would therefore be useful to test 
these hypotheses. 
The objective of this study was to develop method to measure both 
methadone enantiomers and its major metabolite 2-ethylidene-1, 5-
dimethyl-3, 3-diphenylpyrrolidine (EDDP) in clinical 
samples.Methadone is mainly cleared via hepatic metabolism by 
cytochrome P450 (CYP) to the inactive metabolite EDDP through N-
demethylation pathway. EDDP has no pharmacological activity and 
been reported to be of lower concentrations in plasma during 
therapeutic usage. However, measurement of EDDP was imperative 
in order to determine whether preferential metabolism of 
methadone had occurred. 
MATERIAL AND METHODS 
Chemicals and reagents 
S-Methadone, R-methadone, EDDPand deuterium-labeled (R,S)-
[2H3]-Met, were purchased from Cerilliant (Austin, TX, USA). 
Methanol gradient grade for liquid chromatography LiChrosolv® 
Reag. Ph Eur and formic acid (98-100%) was purchased from Merck 
Millipore (Merck KGaA, Darmstadt, Germany),ammonium formate 
99% was obtained fromAcros Organic (Geel, Belgium), and ultra-
pure water wasobtained, using a Milli-Q water-purification system 
(Millipore, Milford, MA, USA).  
Pooled drug-free human plasmawas donated from Blood Bank, 
Hospital Universiti Sains Malaysia, Malaysia. 
For the SPE procedures, mixed mode Si-SCX/C8 columns (SampliQ) 
(100 mg sorbent mass, 1 ml column volume) were purchased from 
Agilent Technologies (USA). Phosphate buffer 0.01 M was prepared 
by dissolving disodium hydrogen phosphate (1.42 g) in water in a 
one litre volumetric flask. pH was adjusted to 6.0 (±0.1)either with 
sodium hydroxide 1.0 M or phosphoric acid. The acetic acidic 
solution 1 M, was prepared by an appropriate dilution of 
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concentrated aceticacid with water. The eluent was acetonitrile-
ammonia (95:5, v/v) and was prepareddaily. 
Instrumentation 
Equipment comprised a Sorvall™ ST 16 Centrifuge (Thermo Fisher 
Scientific™ Inc, Germany);a SIGMA 1-14 microcentrifuge (Sartorius 
Stedim Biotech GmbH, Germany); a Eutech, CyberScan ph1100 pH 
Meter (Fisher Scientific™ Inc, Germany); a Thermolyne vortex shaker 
(Thermo Fisher Scientific™ Inc, Germany) and N-EVAP 24 nitrogen 
evaporator manifold (Organomation Associates, MA, USA). 
Chromatography was performed on an Agilent 1260 infinity with 
G1312B binary pump, G1379B 1260µ degasser, G1316A 
thermostated column compartment, G1367E auto sampler and 6460 
MS QQQ mass spectrometer (Agilent Technologies GmbH, Germany). 
An Astec Chirobiotic V2 (5 µm, 4.6 mm*×250 mm, Sigma-Aldrich Co. 
LLC) was used to separate the compounds.  
Working solution and spiked plasma 
Standard stock solutions of 1 mg/mL R-methadone and S-
methadone were prepared in methanol by appropriately weighing 
the drugs. It were stored at -80ºC until use. Working solutions of R-
methadone, S-methadone, EDDP and methadone-D3 at 10ug/ml in 
methanol were prepared by appropriately diluting the stock in 
methanol. For the preparation of calibration and quality control (QC) 
samples, blankplasma was seeded with appropriate amounts of 
(R,S)-methad one working solutions to obtain a concentration range 
of 5–1000 ng/mL for each methadone enantiomers and 5–
500ng/mL for EDDP. Control samples were included in every run. 
Sample Collection 
This study was approved by Universiti Sains Malaysia Ethical 
Committee. Patients in Methadone Maintenance Therapy program at 
Psychiatric Clinic, Hospital Universiti Sains Malaysia and willing to sign 
an informed consent form were enrolled in this study after two weeks 
stabilized on any dose of methadone. Five millilitres blood were taken 
before subsequent dosing. After each collection, blood samples were 
spun at 3,500rpm and kept the serum at -20ͦ
The final optimized LC separation was performed on a Chirobiotic 
V2 column (5 µm, 4.6 mm× 250 mm, Astec, Whippany, NJ) using 
amobilephase of 5:95 20 mM* ammonium formate: 0.003% formic 
acid in methanol at a flow rate of 0.4 ml*/min and column 
temperature was of6ºC. Injection volume was 1 µL*.  The mass 
spectrometric measurements were performed with a 6460QQQ-MS 
(Agilent Technologies), equipped with an electrospray ionization 
(ESI) source and the Agilent Jet Stream technology. It was operated 
in the positive mode with multiple-reaction monitoring(MRM) under 
optimized conditions for the detection of methadone, EDDP and 
methadone-D3. The monitored mass transitions for methadone and 
methadone-D3 were set at m/z 310.2 → 265.1and 313.2 → 268.1 
(dwell time 20 ms, fragmentor voltage 78 V and collision energy 
9 V). The monitored mass transitions for EDDP were set at m/z 
278.2 → 234.1 (dwell time 20 ms, fragmentor voltage 84 V and 
collision energy 29 V).Nitrogen was used as nebulizer, turbo 
(heater) gas, curtain, and collision-activated dissociation gas. A Jet 
Stream ESI source was operated with capillary voltage of 3,500 V, 
nozzle voltage of 500 V, drying gas temperature of 300 °C, gas flow 
of 5 L/min, nebulizer gas pressure of 45 psi, sheath gas temperature 
of 250 °C and sheath gas flow rate of 11 L/min. Data collection and 
integration were performed using the Mass Hunter workstation 
software (version B.05.00) 
Method Validation 
Linearity  
To establish linearity, a series of calibration curves were constructed 
by analyzing drug free plasma seeded with EDDP to give theoretical 
concentrations of 5, 25, 50, 100, 200, 300, 500 ng/ml, and R- and S-
methadone concentrations of 5, 50, 200, 300, 400, 500, 1000 ng/ml 
of each enantiomer. Quality control (QC) samples in plasma(10, 75, 
150, 400 ng/ml EDDP; 25, 150, 250, 750 ng/ml each R- and S-
methadone) were prepared using separate dilutions of stocks. 
Calibration and QC samples were aliquotted and stored at −20ºC 
until extracted. Calibration and QC samples were analysed daily 
together with the analytical samples. Standard curves were 
constructed using linear regression. Acceptance criteria for the 
calibration curves was a regression coefficient (r2) >0.95and back-
calculated values of calibrations standards that deviated≤15% from 
nominal and less than 20% at the limit of quantification. The limit of 
detection (LOD) was defined as a signal to noise ratio of 2:1. The 
limit of quantification (LOQ) was the lowest concentration on the 
standard curve with an acceptable level of variation (<20%) and a 
signal to noise ratio >10:1. 
Matrix Effect and Recovery 
The matrix effect (ME) was studied by comparing the concentrations 
of quality control standards injected directly in mobile phase (set A) 
with the concentration found of the same analytes spiked after 
extraction (set B)at three levels (LQC, MQC, and HQC). The formula 
used was: ME= set B/set A×100. The recovery (RE) was studied by 
analyzing quality control standards at three levels and comparing 
the concentration of these analytes before extraction (set C) with 
another set of the same analytes after extraction (set B).  
The formula used was: RE = Set C/Set B×100. 
Stability 
Effect of freeze and thaw cycles on the stability of plasma samples 
containing R-methadone, S-methadone and EDDP were determined 
by subjecting six aliquots of low, mid and high unprocessed QC 
samples stored at −70±5 ◦ C to three freeze thaw  cycles. After the 
completion of third cycle, the samples were analyzed. The accuracy 
of this sample set was determined by comparison of untreated QC 
samples extracted and run in the same session. The sample was 
stable if the % change in concentration of the stability samples was 
within ±15% of the theoretical value. 
Accuracy and precision 
Intra-day accuracy and precision were evaluated by replicate 
analysis of R-methadone, S-methadone and EDDP at different 
concentrations. The run consisted of a calibration curve plus six 
replicates each of lower limit, low, medium (mid) and high QC 
samples. The inter-day accuracy and precision were assessed in a 
similar manner on five separate occasions. The evaluation of 
precision was based on the criteria that the, coefficient of variation 
for each concentration level should not be more than 15.0% except 
for the LLOQ, for which it should not be more than 20.0%. Similarly, 
for accuracy, mean values should not deviate by ±15.0% of 
theoretical concentration except for the LLOQ where it should not 
deviate by more than ±20.0% of the actual concentration. 
RESULTS AND DISCUSSIONS 
C until analysis  
Sample preparation 
Prior to solid phase extraction (SPE), all plasma or serum was 
centrifuged at 10,000rpm for 10 minutes. Five hundred microlitres of 
plasma or serum was diluted with 2500 µl* dipotassium phosphate pH 
6 before it was loaded into the SPE column (mixture of C8 and SCX) 
that was pre-conditioned with 1 ml* methanol and 1 ml* of 
dipotassium phosphate pH 6. The column was then washed three 
times. The first wash comprised 1 ml* dipotassium phosphate pH 6, 
the second1 ml* of 1M acetic acid and finally 1 ml* methanol. We used 
a full vacuum pressure for 30 sec* at the final washing step to dry out 
the column. One ml of 5% ammonium hydroxide in acetonitrile was 
used to elute the drugs, applying a pressure of 2.5 mm*Hg. The eluent 
was dried under a nitrogen stream at room temperature. The residue 
was reconstituted with 25 µl* 50% methanol in water. The mixture 
was then transferred into an HPLC micro vials and placed in the auto-
injector receptacles for injections into the HPLC.  
LC and MS conditions 
Methods have been described for chiral determination of methadone 
alone or in combination with EDDP and EDMP in various neat 
sample types, including sera, plasma and urine [9-12]. Most methods 
used alpha1-acid glycoprotein (AGP) column as chiral selector but 
these columns tend to gradually lose separation efficiency with 
prolonged use. In this study we choose macrocyclic glycopeptide as 
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chiral selector because it is capable of separating a broad variety of 
enantiomeric compounds with good efficiency, good column 
loadability, high reproducibility, and long-term stability.  
As recommended by the manufacturer, Chirobiotic V2 column has been 
used as CSP (chiral stationary phase) [13]. With modifications of the 
mobile phase, flow rates and temperature (Table 1), we managed to 
resolve R- and S-methadone characterised by a resolution factor of 2.2.  
The final mobile phase composition for the method was set at (5:95) 
20 mM* ammoniumformate: 0.003% formic acid in methanol. Under 
this condition, analysis was completed in 28 min. Retention times 
forR- and S-methadone were 20.27 and 22.03, respectively and the 
observed enantioselectivity (α) was 1.09(Fig. 1(B)). However, under 
this condition, R- and S-EDPP were only partially resolved.  
The retention time for EDPP was 24.02 min (Fig. 1(C)). Only total 
EDDP concentration could be quantified using this method. There is no 
evidence that EDDP contributes to the adverse effects of methadone. 
In vitro evidence suggests CYP3A4 as the main enzyme in the 
formation of EDDP and this reaction is not enantiospecific [14]. 
 
Table 1: The effect of the formic acid concentration in the mobile phase (5% ammonium formate:95% 0.003 formic acid in methanol), 
flow rate and column temperature; retention time (rt); α: enantioselectivity; Rs: resolution. 
Flow rate 
(ml/min) 












0.5 0.005 10 11.79 12.63 1.07 1.6 
0.5 0.003 10 15.72 16.86 1.07 1.7 





Fig. 1: Representative chromatogram of the serum sample collected before subsequent dosing from a patient who had received 
methadone 95mg/day. The measured concentrations were R-methadone 105ng/ml, S-methadone 39.8ng/ml, EDDP 11.6ng/ml. The 
chromatographic trace obtained using MRM at m/z: (A) 313.2, (B) 310.2, and (C) 278.2 
 
For the simultaneous quantification of R- and S-methadone, as well 
as EDDP, calibration standards were prepared by seeding plasma 
with known amounts of racemic methadone and EDPP. The linearity 
for each enantiomer was determined by performing linear 
regression analysis on the plot of the peak area ratios of each 
enantiomer to internal standard versus concentration. The 
calibration curves of seeded plasma exhibited good linearity for the 
concentration of interest (5-1000 ng/ml for each methadone 
enantiomers, 5-500 ng/ml for EDDP) with correlation coefficients 
greater than 0.99 (Table 2). 
Recovery (RE) of the analytes using mixed-mode (C8/strong cation 
exchange (SCX)) solid phase extraction from plasma was 97% ±0.5 
for R-methadone, 99% ±6.6 for S-methadone and 89% ±2.3; Table 3. 
The matrix effects of R-, S- methadone and EDDP form different pool 
of plasma were investigated using quality control samples at three 
levels (LQC, MQC and HQC). Results are shown in Table 3. The 
average matrix effects (ME) for R-, S- methadone was 90% and for 
EDDP was 95%. 
Precision and accuracy for intra-day and inter-day quality control 
samples are summarized in Table 2, Table 3 and Table 4. The 
coefficients of variation (CV) for both inter-day and intra-day 
determination were less than five for both methadone enantiomers 
and less than 12 for EDDP at medium and high quality control 
samples. For low quality control samples the CV was higher but it 
was still in acceptance limit(Table 4, 5 and 6). Accuracy was ≥ 92% 
for methadone and ≥88% for EDDP. Stability was assessed by 
comparing newly extracted quality control samples and quality 
control samples that underwent three freeze/thaw cycles with those 
extracted and reconstituted in mobile phase. There were no 
significant differences in the mean values between the sample sets.
 
 
 Table 2: Linearity of inter-day calibration samples 
n=5 Slope Intercept R-squared 
R-methadone    
Mean 0.008581 -0.002405 0.9989 
SD 0.000270 0.004110 0.0005 
CV (%) 3.15 -170.86 0.05 
S-methadone    
Mean 0.008617 -0.004937 0.9991 
SD 0.000243 0.007503 0.0005 
CV (%) 2.82 -151.97 0.05 
EDDP    
Mean 0.005160 -0.003409 0.9948 
SD 0.000443 0.003323 0.0037 
CV (%) 8.59 -97.49 0.37 
Linear weighted 1/x. The three curves were prepared and run on five different days. 
Table 3: Results of the extraction recovery, matrix effects and stability after three cycles freeze and thawed on the extraction of 
methadone and EDDP. 
 Extraction Recovery (%) Matrix effects (%) Freeze and thaw (3 cycles) (%) 
 Methadone EDDP Methadone EDDP Methadone EDDP 
 R S R S R S 
LQC 97 96 91 95 93 99 97 103 91 
MQC 98 94 90 90 93 96 94 88 86 
HQC 97 106 87 85 84 91 95 97 86 
Mean 97 99 89 90 90 95 95 96 88 
SD 0.5 6.6 2.3 4.9 5.5 4.1 1.7 7.6 3.0 
CV 0.5 6.7 2.6 5.5 6.1 4.3 1.8 7.9 3.4 
 
Table 4: Accuracy and precision of quality control samples for R-methadone 
Intraday (n=6)  LLQC LQC MQC HQC 
(ng/ml)  25 150 250 750 
Day 1 Mean (+ SD) 26.6 + 1.7 153.1 + 3.9 261.0 + 9.1 716.0 + 15.5 
 CV 6.4 2.5 3.5 2.2 
 Accuracy (%) 106.3 102.1 104.4 95.5 
 Bias % 6.3 2.1 4.4 -4.5 
Day 2 Mean (+ SD) 24.6 + 1.2 147.8 + 7.1 245.7 + 12.7 688.7 + 21.5 
 CV 5.1 4.8 5.2 3.1 
 Accuracy (%) 98.4 98.5 98.3 91.8 
 Bias % -1.6 -1.5 -1.7 -8.2 
Day3 Mean (+ SD) 24.6 + 1.2 150.6 + 5.1 249.9 + 5.3 706.3 + 19.7 
 CV 4.8 3.4 2.1 2.8 
 Accuracy (%) 98.4 100.4 100.0 94.2 
 Bias % -1.6 0.4 0.0 -5.8 
Day4 Mean (+ SD) 25.4 + 0.9 151.89 + 3.6 249.6 + 3.0 724.3 + 12.0 
 CV 3.4 2.4 1.2 1.7 
 Accuracy (%) 101.6 101.3 99.8 96.6 
 Bias % 1.6 1.3 -0.2 -3.4 
Day5 Mean (+ SD) 25.2 + 0.7 143.4 + 3.7 242.7 + 9.8 712.1 + 24.7 
 CV 2.7 2.6 4.0 3.5 
 Accuracy (%) 100.8 95.6 97.1 94.9 
 Bias % 0.8 -4.4 -2.9 -5.1 
Inter- day (n=5) Mean (+ SD) 25.3+ 0.8 149.4+ 3.9 249.8+ 6.9 709.5+ 13.3 
 CV 3.2 2.6 2.8 1.9 
 Accuracy (%) 101.1 99.6 99.9 94.6 
 Bias % 1.1 -0.4 -0.1 -5.4 
 
Table 5: Accuracy and precision of quality control samples for S-methadone 
Intraday (n=6)  LLQC LQC MQC HQC 
(ng/ml)  25 150 250 750 
Day 1 Mean (+ SD) 26.4 + 1.0 157.8 + 8.1 260.4 + 10.3 712.2 + 4.9 
 CV 3.7 5.1 3.9 0.7 
 Recovery %) 105.4 105.2 104.2 95.0 
 Bias % 5.4 5.2 4.2 -5.0 
Day 2 Mean (+ SD) 25.0 + 0.8 150.8 + 5.1 251.8 + 11.3 706.0 + 24.6 
 CV 3.1 3.4 4.5 3.5 
 Recovery %) 99.9 100.5 100.7 94.1 
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 Bias % -0.1 0.5 0.7 -5.9 
Day 3 Mean (+ SD) 27.7 + 1.3 148.7 + 4.9 245.8 + 6.4 700.2 + 18.5 
 CV 4.7 3.3 2.6 2.6 
 Recovery %) 110.8 99.1 98.3 93.4 
 Bias % 10.8 -0.9 -1.7 -6.6 
Day 4 Mean (+ SD) 24.8 + 1.1 149.9 + 5.6 249.5 + 11.3 706.7 + 15.1 
 CV 4.5 3.8 4.5 2.1 
 Recovery %) 99.0 99.9 99.8 94.2 
 Bias % -1.0 -0.1 -0.2 -5.8 
Day 5 Mean (+ SD) 24.6 + 1.0 150.9 + 9.6 251.8 + 10.7 698.2 + 28.84 
 CV 4.1 6.4 4.2 4.1 
 Recovery %) 98.4 100.6 100.7 93.1 
 Bias % -1.6 0.6 0.7 -6.9 
Inter-day (n=5)      
 Mean (+ SD) 25.7+ 1.3 151.6+ 3.6 251.9+ 5.4 704.7+ 5.6 
 CV 5.2 2.4 2.1 0.8 
 Recovery (%) 102.7 101.1 100.7 94.0 
 Bias % 2.7 1.1 0.7 -6.0 
 
Table 6: Accuracy and precision of quality control samples for EDDP 
Intraday (n=6)  LLQC LQC MQC HQC 
(ng/ml)  10 75 150 400 
Day 1 Mean (+ SD) 10.0 + 0.7 77.5 + 3.5 147.4 + 9.5 406.1 + 47.8 
 CV 7.4 4.5 6.5 11.8 
 Accuracy (%) 100.1 103.3 98.3 101.5 
 Bias % 0.1 3.3 -1.7 1.5 
Day 2 Mean (+ SD) 10.3 + 0.8 77.2 + 6.6 153.7 + 14.0 369.2 + 28.4 
 CV 7.6 8.6 9.1 7.7 
 Accuracy (%) 102.7 102.9 102.4 92.3 
 Bias % 2.7 2.9 2.4 -7.7 
Day 3 Mean (+ SD) 9.8 + 1.6 71.1 + 4.8 140.5 + 14.1 363.1 + 41.9 
 CV 16.1 6.8 10.0 11.5 
 Accuracy (%) 98.5 94.8 93.7 90.8 
 Bias % -1.5 -5.2 -6.3 -9.2 
Day 4 Mean (+ SD) 11.2 + 1.1 75.8 + 2.4 149.0 + 16.6 357.7 + 32.9 
 CV 9.3 3.1 11.1 9.2 
 Accuracy (%) 112.4 101.1 99.3 89.4 
 Bias % 12.4 1.1 -0.7 -10.6 
Day 5 Mean (+ SD) 9.5 + 1.2 71.4 + 4.3 132.6 + 6.4 353.8 + 34.0 
 CV 13.0 6.1 4.8 9.6 
 Accuracy (%) 94.8 95.2 88.4 88.5 
 Bias % -5.2 -4.8 -11.6 -11.5 
Inter- day (n=5)      
 Mean (+ SD) 10.2 + 0.7  74.6 + 3.1 144.6 + 8.2 370.0 + 21.0 
 CV 6.5 4.2 5.7 5.7 
 Accuracy (%) 102.0 99.5 96.4 92.5 
 Bias % 1.7 -0.5 -3.6 -7.5 
Table 7: The concentration of methadone (met) enantiomers and EDDP in serum samples from patients in a methadone maintenance 
program with different dose. 
Subjects Age (year) Dose (mg) R-met (ng/ml) S-met (ng/ml) R/Smet ratio EDDP (ng/ml) Metabolic ratio 
1 40 70 127.5 93.7 1.4 15.2 8.4 
2 38 80 196.6 177.0 1.1 27.0 7.3 
3 39 65 76.2 54.5 1.4 5.6 13.6 
4 23 20 132.0 233.6 0.6 8.2 16.0 
5 31 120 127.2 72.5 1.8 17.6 7.2 
6 42 70 164.6 124.7 1.3 17.2 9.5 
7 37 65 85.5 60.2 1.4 12.3 6.9 
8 42 80 222.2 155.1 1.4 39.7 5.6 
9 40 95 105.0 39.8 2.6 11.6 9.1 
10 37 25 60.1 65.3 0.9 4.5 13.4 
Mean 37 69 129.7 107.6 1.4 15.9 9.7 
SD 5.8 29.6 52.2 63.4 0.5 10.7 3.5 
CV (%) 15.8 42.9 40.3 58.9 39.2 67.0 35.7 
 
Applications to clinical samples 
The validated method was applied to serum samples of patients on 
the national methadone maintenance treatment (MMT) program. In 
this study, serum samples were obtained at steady state before the 
next dose. The average R/S-met ratio was 1.4±0.5 with a range 0.6-
2.6 (Table 7). Our results are consistent with previous observations 
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[9, 10]. It will be applied to measure concentrations of methadone 
enantiomers and its main metabolite (EDDP). 
CONCLUSIONS 
To the best ofour knowledge, this is the first report of the use of V2 
column in the LC/MS/MS quantitation of methadone enantiomers in 
human plasma and serum without matrix effects even though the 
baseline separation of the enantiomers were achievable after 20 
minutes. This validated assay offers same sensitivity, linear range 
and ruggedness over previously published method using different 
chiral selector. 
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